Sleep Disorder Market Size & Share 2026-2035

Sleep Disorder Market Size

The global sleep disorder market was valued at USD 30.5 billion in 2025 and is estimated to reach USD 33.8 billion in 2026. The market is projected to reach USD 78.6 billion by 2035, expanding at a CAGR of approximately 9.8% from 2026 to 2035. The revenue base spans diagnosis and management of conditions with different treatment pathways, but obstructive sleep apnea (OSA) is the central commercial anchor: a literature-based estimate places mild-to-severe OSA among adults aged 30–69 at 936 million people globally ^{[1]Benjafield A.V. et al., Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis, fredi.hepvs.ch}. Chronic insomnia creates a second large demand pool, affecting an estimated 852 million adults worldwide, while restless legs syndrome affects an estimated 356 million adults.

The distance between prevalence and treated prevalence explains why market expansion can persist even as established PAP therapy becomes more mature. Untreated OSA carries costs beyond sleep-clinic care, including higher healthcare use, lost productivity, and road-safety exposure; one recent review puts its annual U.S. societal burden above USD 150 billion ^{[2]Vourc'h M. et al., The Global Socioeconomic Burden of Obstructive Sleep Apnea: A Comprehensive Review, 2025, mdpi.com}. That economic burden gives payers a reason to finance treatment, but the practical path from symptoms to therapy still depends on diagnostic capacity, reimbursement, and patient tolerance of treatment.

Care delivery is increasingly moving outside the sleep laboratory. Medicare covers CPAP as durable medical equipment for qualifying beneficiaries, subject to the program's coverage conditions. At the same time, home sleep apnea testing (HSAT) has become a validated option for adults with a high pre-test probability of uncomplicated OSA, reducing the facility dependence of first-line testing. Connected PAP devices and consumer screening products extend this shift by making ongoing monitoring and symptom recognition possible in the home.

The boundary condition is affordability. OSA's economic burden supports payer intervention, yet coverage rules, laboratory supply, and patient out-of-pocket exposure determine whether prevalence becomes revenue. Companies able to connect screening, diagnostic confirmation, and adherence support are better positioned than vendors selling a single disconnected product; however, consumer screening remains a route to clinical assessment rather than a substitute for diagnosis.

Key Drivers

Expanding clinical burden and referral urgency

Sleep-disordered breathing is increasingly managed alongside cardiometabolic disease rather than solely within specialist sleep clinics. OSA is associated with hypertension, diabetes, and cardiovascular risk, widening the group of clinicians who can identify candidates for testing. The ageing and obesity-linked risk profile is particularly consequential because it increases demand for repeatable diagnostic and treatment pathways, not merely episodic consultation. Insomnia also broadens the addressable market beyond respiratory sleep medicine: its scale supports behavioral, digital, and pharmacological care models, although these models do not share the same equipment economics as PAP therapy.

Awareness is becoming more measurable in the United States. In 2024, 15.4% of adults reported trouble falling asleep and 18.1% reported trouble staying asleep. Those measures do not equate to diagnosed disease, but they enlarge the pool that may seek evaluation. The commercial consequence is greatest when awareness is paired with a practical referral route; education alone cannot resolve laboratory queues, reimbursement limitations, or therapy abandonment.

Decentralized diagnostics and connected therapy

HSAT changes the cost and operating model of uncomplicated OSA evaluation. FDA-cleared Type 3 systems measure airflow, respiratory effort, and oxygen saturation and have gained importance in clinical pathways for appropriate adult patients. By reserving laboratory polysomnography for complex, pediatric, inconclusive, or non-respiratory presentations, providers can direct scarce technician and laboratory capacity toward cases that need it most.

Technology is also being directed at the adherence problem after prescription. In December 2025, ResMed announced FDA clearance for Smart Comfort, a feature intended to recommend personalized CPAP comfort settings for new AirSense 11 users ^{[3]ResMed Inc., ResMed Receives FDA Clearance for Personalized Therapy Comfort Settings (Smart Comfort), December 2025, investor.resmed.com}. The company stated that the feature was trained on more than 100 million nights of de-identified data. Its importance is not simply the addition of AI terminology: if comfort recommendations improve sustained use, they can protect the recurring mask, supply, service, and reimbursement economics that underpin PAP therapy.

Consumer devices are widening the front end of the funnel. Apple's Sleep Apnea Notification Feature received FDA 510(k) clearance in September 2024 for certain Apple Watch models, and Apple subsequently made watchOS 11 available with the feature in supported markets. The notification identifies patterns consistent with possible sleep apnea; it does not establish a diagnosis. That distinction preserves the role of clinical testing while allowing consumer hardware to create more informed referrals.

Home-based care and portable device demand

The 58.5% 2025 share held by home care settings & individuals reflects more than convenience. A home pathway aligns with CPAP reimbursement, DME distribution, remote compliance tracking, and recurring replacement supplies. Medicare's rental-to-ownership structure for qualifying CPAP beneficiaries illustrates how reimbursement can make a home-based model operationally viable.

Device design has become central to this shift because comfort can determine whether a patient remains on therapy. Fisher & Paykel Healthcare reported that its Homecare product group grew 18% to USD 652 million in FY2024, while the company highlighted mask innovations including its Nova Micro product. Lighter masks, humidification, quieter operation, and app-based monitoring address different points of friction in the same home-treatment workflow. In practical terms, manufacturers increasingly compete on the quality of ongoing therapy experience rather than on initial pressure delivery alone.

Key Restraints

Cost and reimbursement discontinuities

The diagnostic-to-treatment pathway remains expensive where coverage is incomplete. A review of OSA economics reports that U.S. laboratory polysomnography can cost USD 1,000–3,500 and identifies ongoing costs for PAP equipment and supplies as a barrier to care. Medicare coverage mitigates that burden for eligible beneficiaries, but it also requires qualifying documentation and cost sharing. The result is a market in which clinical need does not automatically become treatment initiation.

Funding policy has a direct effect on modality choice. Research reported by Healio found that regional CPAP funding conditions influenced patients' treatment decisions and diagnostic routes. This is commercially important because a low-cost device can still be inaccessible when the patient faces an uncovered study, a high deductible, or fragmented supply arrangements. It also makes price architecture and local reimbursement capability more important than global prevalence when assessing near-term market potential.

Shortage of sleep-medicine capacity in developing regions

In many emerging markets, the constraint is physical access before it is device preference. A review of sleep medicine in Africa identified 41 sleep laboratories across four countries and highlighted shortages in awareness, funding, trained staff, and facilities ^{[4]Mbaye E.M. et al., Sleep medicine in Africa: past, present, and future, 2022, link.springer.com}. Brazil faces a similar imbalance: a 2024 study documented 47 identified sleep centers, uneven distribution across federal units, and long waits for diagnostic assessment.

India illustrates the interaction between capacity and policy. Commentary on sleep testing has pointed to limited access outside major cities and to reimbursement structures that do not routinely support HSAT under the Central Government Health Scheme. Home testing could relieve part of this bottleneck, but only where clinicians, payers, regulation, connectivity, and service networks support its use. Portable hardware without those complementary conditions cannot independently scale treated prevalence.

The commercial opportunity lies in designing a viable care pathway, not merely in shipping lower-priced equipment. Manufacturers with local distribution, training, remote support, and reimbursement partnerships can make decentralized care more durable. Conversely, transferring a premium-market PAP model unchanged into markets with weak funding risks low conversion after diagnosis and limited repeat-supply revenue.

Sleep Disorder Market Segment Analysis

By Disorder Type

Sleep apnea

Sleep apnea held 48.2% of global market revenue in 2025 and is projected to exceed USD 39.8 billion by 2035, expanding at a 10.3% CAGR. Its lead reflects both prevalence and a defined treatment architecture: screening and diagnostic testing can lead to PAP therapy, followed by monitoring and recurrent supplies. OSA's association with cardiometabolic conditions also extends referral sources beyond sleep specialists. Central and complex sleep apnea are smaller, but their management can require more specialized equipment, including adaptive servo-ventilation, which supports higher-value clinical pathways.

Insomnia

Insomnia generated USD 6.8 billion in 2025 and is projected to grow at a 9.6% CAGR. Unlike OSA, its revenue pool is distributed across behavioral interventions, digital programs, and medicines rather than dominated by a durable medical device. The high global burden supports continued demand ^{[5]Leger D. et al., Estimation of the global prevalence and burden of insomnia in adults: systematic review, 2025, pmc.ncbi.nlm.nih.gov}, but commercial success depends on adherence to multi-session behavioral care and on reimbursement acceptance for digital delivery. This creates room for lower-cost scalable interventions while limiting direct comparability with PAP-device revenue.

Restless legs syndrome

Restless legs syndrome generated significant revenue in 2025 and is forecast to grow at a 10% CAGR. Its estimated 356 million affected adults support recurring pharmacological management, particularly when symptoms are persistent or severe. The segment's growth profile is shaped by medication selection and long-term monitoring rather than home diagnostic hardware, making it a clinically important but operationally distinct component of the broader market.

Narcolepsy

Narcolepsy is projected to expand at an 8.9% CAGR. Its lower population base relative to OSA or insomnia limits volume, but lifelong management and specialized therapies produce high value per treated patient. The commercial constraint is not diagnostic throughput alone; it is the smaller eligible population and the need for specialist-led care, which concentrates demand in established clinical networks.

By Product

Therapeutics

Therapeutics generated USD 19.2 billion in 2025 and are projected to advance at a 10.2% CAGR. PAP devices remain the principal therapeutic platform for OSA, while oral appliances offer an alternative for selected patients and behavioral interventions address insomnia. The segment's superior growth rate versus diagnostics is consistent with the longer-duration economics of therapy: initial diagnosis can be a discrete event, whereas treatment creates ongoing requirements for hardware support, consumables, monitoring, or repeated clinical care.

Connected PAP systems add a service layer to this model. Remote monitoring may help providers verify use and intervene when comfort or adherence falters; it can also help manufacturers differentiate in a market where baseline pressure delivery is increasingly standardized. That value proposition is strongest when the system integrates device, software, and patient support, rather than when connectivity is sold as a standalone feature.

Diagnostics

Diagnostics are forecast to grow at a 9.1% CAGR. Laboratory PSG remains necessary when a full physiological study is clinically required, but HSAT permits a lower-intensity route for many uncomplicated OSA cases ^{[6]Kapur V.K. et al., FDA-cleared home sleep apnea testing devices, 2024, nature.com}. The resulting product mix does not imply that home testing replaces laboratories. Instead, it redistributes testing so laboratories can focus on complex cases, while home devices expand capacity for routine evaluation.

Wearables add a separate screening layer. FDA-cleared functions such as Apple's sleep apnea notification can prompt clinical follow-up, while rings, watches, pulse oximeters, and non-wearable monitors normalize sleep tracking. Their strategic relevance lies in earlier symptom recognition and referral generation. Clinical confirmation remains essential, particularly where treatment eligibility and reimbursement depend on a qualifying study.

By End Use

Home care settings & individuals

Home care settings & individuals held 58.5% of global market share in 2025 and are projected to reach USD 46.9 billion by 2035. The segment combines HSAT, PAP initiation, telemonitoring, and recurring supplies in a single patient-centered pathway. Reimbursement support for home CPAP in the U.S. reinforces that structure, while mask comfort and remote assistance determine whether it delivers sustained therapy rather than a one-time device sale.

Sleep laboratories & hospitals

Sleep laboratories & hospitals are projected to expand at a 9.5% CAGR. Their role is becoming more selective, not dispensable: comprehensive PSG, pediatric studies, complicated respiratory presentations, and non-respiratory sleep disorders still require institutional capability. Hospitals also remain the referral hub for patients whose sleep disorders intersect with neurology, cardiology, or pulmonary care. This preserves demand for high-channel diagnostic systems even as routine OSA testing decentralizes.

The emerging architecture is layered rather than substitutive. Consumer technology can flag risk, HSAT can confirm many routine OSA cases, and laboratories retain responsibility for complex evaluation. Companies that participate across these layers can reduce handoffs and improve continuity, but they must remain clear about the clinical boundary between screening and diagnosis. That boundary will shape both regulatory credibility and payer acceptance.

Sleep Disorder Market Regional Analysis

North America

North America held 38.1% of global market share in 2025. The U.S. market rose from USD 8.1 billion in 2022 to USD 8.9 billion in 2023, USD 9.7 billion in 2024, and USD 10.7 billion in 2025; it is projected to grow at an 8.7% CAGR through 2035. Medicare's CPAP coverage pathway gives suppliers and DME providers a predictable framework for qualifying patients, although CMS continues to monitor documentation and payment compliance for CPAP claims,.

The Philips Respironics recall materially altered PAP competition in the region. In April 2024, a federal court consent decree restricted production and sale of new Philips sleep apnea devices in the U.S. pending remediation requirements ^{[7]Reuters, U.S. federal court orders Philips to restrict production of sleep apnea devices, April 2024, reuters.com}. This disruption favored other suppliers with available capacity, but it also highlighted the value of supply continuity and regulatory quality systems in a category dependent on regular device and accessory availability.

United States, Canada

The United States is the region's principal commercial market, supported by reimbursement, established DME channels, and a large sleep-medicine ecosystem. Canada offers advanced care infrastructure, although provincial differences in reimbursement and service availability influence adoption of HSAT and portable diagnostics.

Europe

Europe generated USD 9 billion in 2025. Public funding and established sleep-medicine services support demand in Germany, the UK, France, Spain, Italy, and the Netherlands. Economic evidence is a material policy driver: a European review estimated that five major sleep disorders impose approximately EUR 422.9 billion in annual costs across high-income European countries ^{[8]Bassetti C.L.A. et al., Epidemiology and Economic Burden of Sleep Disorders in Europe, 2025, pmc.ncbi.nlm.nih.gov}. That burden supports interest in earlier diagnosis and treatment, though public procurement and evidence requirements can lengthen adoption cycles.

Regulation also creates institutional demand. EU rules on driver licensing include requirements related to moderate and severe OSA, extending sleep assessment beyond self-referred patients. At the same time, medical-device compliance requirements raise the evidentiary and operational threshold for new entrants. The outcome is a large but carefully regulated market in which reimbursement and clinical validation matter as much as consumer awareness.

Germany, UK, France, Spain, Italy, Netherlands

Germany's statutory insurance and digital-health framework make it a key market for connected and digitally delivered care. The UK and France sustain significant institutional demand, while national pathways and service queues create uneven openings for private and home-based alternatives.

Asia Pacific

Asia Pacific is projected to grow at an 11.3% CAGR, the highest among regions. The growth premium reflects large underdiagnosed populations and expanding health-system capacity rather than an already mature reimbursement base. China has the largest absolute OSA burden in the underlying prevalence literature, while India combines substantial need with uneven diagnostic access.

The regional opportunity is therefore operationally demanding. Urban hospitals and private providers can adopt PSG, HSAT, PAP, and remote monitoring quickly, but expansion beyond major cities depends on affordable testing, local distribution, clinician training, and payment pathways. Japan, South Korea, and Australia offer more developed diagnostic and reimbursement settings; China and India offer scale but require more localized commercial models.

China, Japan, India, Australia, South Korea

China and India provide the largest long-term volume opportunity. Japan, South Korea, and Australia contribute higher near-term clinical sophistication and can support earlier adoption of connected diagnostics and therapy.

Latin America

Latin America remains a high-need market with constrained conversion to treatment. Brazil, Mexico, and Argentina are the principal markets, but Brazil's documented shortage and uneven distribution of sleep centers demonstrate the gap between clinical need and available service. Long diagnostic waits and incomplete public funding limit the pace at which patients enter PAP therapy.

Home testing and telemedicine could improve reach, but their impact depends on pricing, referral systems, and availability of follow-on treatment. For suppliers, the most credible regional proposition is a lower-infrastructure pathway that connects screening, testing, and device support rather than a laboratory-intensive model transplanted from North America.

Brazil, Mexico, Argentina

Brazil is the region's main reference market because of its population scale and documented service gaps. Mexico and Argentina offer private-sector opportunities, but affordability and fragmented access remain central constraints.

Middle East and Africa

The Middle East and Africa combine premium urban opportunities with severe capacity constraints. Saudi Arabia has an established but geographically concentrated sleep-medicine base, while the UAE can support premium diagnostic and therapeutic products through its private healthcare infrastructure. Elsewhere, particularly in Sub-Saharan Africa, the lack of laboratories and trained personnel sharply restricts treated prevalence.

This regional contrast makes one uniform strategy unsuitable. In Gulf markets, suppliers can pursue specialist and hospital channels; in lower-resource markets, viable expansion depends on robust portable technology, training, service support, and payment models that accommodate constrained infrastructure.

South Africa, Saudi Arabia, UAE

Saudi Arabia and the UAE are the region's most accessible markets for specialist-led care. South Africa provides a regional clinical base, but capacity is modest relative to the wider population need.

That distinction changes market-entry priorities. In mature regions, differentiation depends on adherence, service, clinical evidence, and supply reliability. In Asia Pacific, Latin America, and much of MEA, the immediate challenge is building the pathway around the product: access to testing, trained interpretation, financing, and post-diagnosis support. Companies that treat these as separate regional operating models will be better placed than those relying on a single global launch template.

Sleep Disorder Market Share & Competitive Landscape

The market is concentrated in PAP therapy and related interfaces, where ResMed, PHILIPS, Fisher & Paykel Healthcare, BMC Medical, and Drive Devilbiss collectively account for approximately 67% of global share. Competition broadens in diagnostics and consumer monitoring, where clinical validation, sensor capability, software, and channel access become as important as respiratory-device scale.

Apple participates through consumer screening. Its FDA-cleared sleep apnea notification feature can direct users toward formal evaluation but does not provide a diagnosis.

BMC Medical is an authorized company in the PAP device portfolio, with relevance in clinical and home-use respiratory therapy.

Cadwell serves the diagnostic side of the market through neurodiagnostic and sleep-study equipment used in laboratory settings.

Drive Devilbiss participates through respiratory and home-care equipment channels, including sleep therapy products and accessories.

Fisher & Paykel Healthcare competes strongly in OSA masks and humidification. Its FY2024 Homecare revenue of USD 652 million, up 18%, illustrates the commercial importance of the patient-interface category ^{[9]Fisher & Paykel Healthcare, FY24 Full Year Result: Revenue and Earnings Announcement, May 2024, fphcare.com}.

Natus serves sleep laboratories through neurodiagnostic monitoring systems and related clinical instrumentation.

Nihon Kohden participates in patient monitoring and neurodiagnostics, including systems relevant to polysomnography and EEG-based evaluation.

Oura Health operates at the consumer-health end of the market. In December 2024, the company raised USD 200 million at a USD 5.2 billion valuation, according to TechCrunch. Its strategic relevance is the use of continuous wearable data to engage users in sleep and broader preventive-health monitoring.

PHILIPS retains a significant market presence, but its competitive position has been constrained by the recall-related U.S. consent decree and a USD 1.1 billion U.S. litigation settlement announced in April 2024.

ResMed is a leading PAP and connected-care participant. It reported USD 4.7 billion in FY2024 revenue and described a global base of cloud-connected devices and medical sleep data. Smart Comfort extends its effort to use that data infrastructure in therapy personalization.

Sleep Shepherd addresses a consumer wellness niche through sleep-oriented audio headbands rather than prescription therapy.

Sleepace participates in consumer sleep analytics, including non-wearable and wearable monitoring products.

WEINMANN Medical competes in PAP, bilevel ventilation, and respiratory-care equipment, particularly in European clinical and home-care settings.

WITHINGS offers non-wearable consumer sleep monitoring, including under-mattress tracking designed to identify sleep and breathing indicators.

ZOLL Medical is relevant primarily in ventilatory support and complex respiratory management rather than mass-market OSA therapy.

Recent Industry Developments

December 2025 - ResMed receives FDA clearance for Smart Comfort

ResMed announced FDA clearance on December 8, 2025, for Smart Comfort, a feature designed to recommend personalized therapy comfort settings for people initiating CPAP therapy with AirSense 11. The planned U.S. beta launch was expected in early 2026. The development targets a practical barrier to PAP value creation: patients who discontinue therapy do not realize the expected clinical benefit and do not sustain the related supply and service cycle.

January 2026 - Inogen launches Aurora CPAP masks

Inogen announced the U.S. launch of Aurora CPAP masks on January 7, 2026, marking its entry into the OSA mask market. The three-mask portfolio is intended for broad CPAP compatibility and will use Inogen's established partner distribution network. The event introduces a new participant into an interface category where fit, comfort, and replacement cycles are strategically important.

December 2024 - Oura Health closes USD 200 million funding round

Oura closed a USD 200 million funding round in December 2024 at a USD 5.2 billion valuation. Dexcom's participation and the companies' stated interest in integrating sleep and metabolic data point to a broader consumer-health platform strategy rather than a standalone sleep-tracking proposition.

September 2024 - Apple Watch sleep apnea notification feature receives FDA clearance

The FDA cleared Apple's Sleep Apnea Notification Feature on September 13, 2024. The feature uses Apple Watch data to notify users of signs consistent with sleep apnea, creating a consumer entry point that may increase referrals for confirmatory testing.

April 2024 - Philips recall-related settlement and U.S. consent decree

Philips announced a USD 1.1 billion U.S. settlement in April 2024 concerning personal-injury and medical-monitoring claims related to its recalled sleep and respiratory devices. A separate federal consent decree restricted the production and sale of new Philips sleep apnea devices in the U.S. pending remediation compliance.